Q2 2026 Champions Oncology Inc Earnings Call Transcript
Key Points
- Champions Oncology Inc (CSBR) reported a year-over-year revenue increase of 11%, reaching $15 million, driven by improved conversion of booked work and reduced cancellations.
- The company achieved a gross margin of 52%, up from 45% the previous year, reflecting improved operational efficiencies.
- Champions Oncology Inc (CSBR) is uniquely positioned in the market with its specialized radio labeling capabilities, which are in high demand within oncology drug development.
- The company is making strategic investments in its data platform, enhancing its functionality and expanding its utility for pharma partners, which is expected to be a critical long-term value driver.
- Champions Oncology Inc (CSBR) maintains a solid financial position with $8.5 million in cash and no debt, supporting its growth initiatives without shareholder dilution.
- Operating expenses increased by $2 million compared to the previous year, primarily due to investments in the data platform and commercial team, impacting short-term profitability.
- The company experienced a net cash outflow of $1.9 million from operating activities during the quarter, driven by a decrease in deferred revenue.
- Despite improvements, the broader pharma and biotech funding environment has not fully recovered, posing challenges to growth.
- The transition of radio labeling work in-house is still ongoing, which may lead to temporary fluctuations in margins due to outsourced service costs.
- Corelli, a wholly owned subsidiary, continues to impact the P&L until external funding is secured, which may not occur until fiscal 2027.
Greetings. Welcome to the Champions Oncology second quarter fiscal year 2026 earnings call. (Operator Instructions) Please note this conference is being recorded.
I will now turn the conference over to your host, Rob Brainin, Chief Executive Officer. You may begin.
Good afternoon and thank you for participating in our second quarter fiscal 2026 earnings call. I'm joined today by our CFO David Miller. Before we begin, I'll remind you that today's remarks may include forward-looking statements. Actual results may differ materially, and more information can be found in our filings with the SEC.
Before we get into the quarter, I want to ground everyone in our three core goals for the year. One, deliver year on year revenue growth. Scaling matters, and we can get margin leverage in our core US business as we grow. Two, invest in our big growth levers, especially our data platforms, which opens the door to more strategic biopharma relationships. And three, stay fiscally
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
